Treatment of type 1 diabetes
AssigneeNovo Nordisk A/S
InventorsThomas Dyrberg, Anne Worsaae
Life of this patent
Estimating the term…
Abstract
Insulin analogues which are substantially devoid of hypoglycemic effect can be used for treating of delaying the onset of type 1 diabetes or ameliorating of an early stage thereof in a mammal at risk of developing diabetes.
Claims8
A method of treating type 1 diabetes in a mammal at risk of developing type 1 diabetes, which method comprises administering parenterally to said mammal a pharmaceutical composition consisting essentially of an effective amount of a hormonally inactive insulin analogue selected from the group consisting of desA1 human insulin, des(A1-A2) human insulin, des(A1-A3) human insulin, desA21 human insulin, des(B1-B5) human insulin, des(B1-B6) human insulin, des(B24-B30) human insulin, des(B25-B30) human insulin, GlyA2 human insulin, AlaA2 human insulin, NleA2 human insulin, ThrA2 human insulin, ProA2 human insulin, D-allo lleA2 human insulin, NvaA3 human insulin, NleA3 human insulin, LeuA3 human insulin, ValA2,IleA3 human insulin, AbuA2,AbuA3 human insulin, GlyA2,GlyA3 human insulin, D-CysA6 human insulin, D-CysA6,D-CysA11human insulin, SerA6,SerA11,des(A8-A10) human insulin, D-CysA7 human insulin, D-CysA11 human insulin, LeuA19 human insulin, GlyB6 human insulin, GluB12 human insulin, AsnB12 human insulin, PheB12 human insulin, D-AlaB12 human insulin, and AspB25 human insulin.
A method of ameliorating type 1 diabetes in a mammal comprising parenterally administering to the mammal an effective amount of a hormonally inactive insulin analogue selected from the group consisting of:
- desA1 human insulin, des(A1-A2) human insulin, des(A1-A3) human insulin, desA21 human insulin, des(B1-B5) human insulin, des(B1-B6) human insulin, des(B24-B30) human insulin, des(B25-B30) human insulin, GlyA2 human insulin, AlaA2 human insulin, NleA2 human insulin, ThrA2 human insulin, ProA2 human insulin, D-allo IleA2 human insulin, NvaA3 human insulin, NleA3 human insulin, LeuA3 human insulin, ValA2,IleA3 human insulin, AbuA2 AbuA3 human insulin, GlyA2GlyA3 human insulin, D-CysA6 human insulin, D-CysA6 D-CysA11 human insulin, SerA6 SerA11 des(A8-A10) human insulin, D-CysA7 human insulin, D-CysA11 human insulin, LeuA19 human insulin, GlyB6 human insulin, GluB12 human insulin, AsnB12 human insulin, PheB12 human insulin, D-AlaB12 human insulin, and AspB25 human insulin.
Dependencies are inferred from the claim text.